Ascentage Pharma Group International (AAPG)vsVertex Pharmaceuticals Inc (VRTX)
AAPG
Ascentage Pharma Group International
$22.32
0.00%
HEALTHCARE · Cap: $1.79B
VRTX
Vertex Pharmaceuticals Inc
$448.62
+1.42%
HEALTHCARE · Cap: $115.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2973% more annual revenue ($12.00B vs $390.60M). VRTX leads profitability with a 32.9% profit margin vs -296.8%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
AAPG
Avoid15
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AAPG.
Margin of Safety
+37.4%
Fair Value
$716.04
Current Price
$448.62
$267.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 79.7x book value
ROE of -159.7% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
AAPG has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : AAPG
The primary concerns for AAPG are EPS Growth, Market Cap, Price/Book.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AAPG profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.87 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (66/100 vs 15/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?